综合分析的不良事件的形状变化与pertuzumab添加到基于trastuzumab的乳腺癌治疗:不成比例的分析使用VigiBase
Tatsuaki Takeda1,2, Jun Matsumoto1,2,3, Tomonori Sakai2,4
1Department of Education and Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Okayama University, Okayama, Japan.
这项研究分析了对HER2阳性乳腺癌患者的珀图祖马布的真实安全数据. 添加祖马布到基于祖马布的治疗增加了胃肠道,皮肤和感染相关不良事件的风险.
科学领域:
- 在瘤学瘤学.
- 药物监督 药物监督 药物监督
- 临床药理学 临床药理学
背景情况:
- 珀图祖马布是治疗HER2阳性乳腺癌的关键疗法,通常与特鲁祖马布一起使用.
- 有限的现实世界安全数据存在于联合治疗方案中对pertuzumab.
- 了解不良事件概况对于患者安全至关重要.
研究的目的:
- 评估添加珀图祖马布的现实世界的安全性,以特鲁祖马布为基础的治疗为HER2阳性乳腺癌.
- 为了确定与珀图祖马布联合治疗相关的特定不良事件.
- 为明智的临床决策提供数据.
主要方法:
- 利用了世卫组织全球不良事件数据库VigiBase (1967-2023年).
- 使用报告几率比率 (ROR) 来检测珀图祖马布的安全信号.
- 在接受基于pertuzumab的治疗方案的乳腺癌患者中分析了不良事件.
主要成果:
- 珀图祖马布加上特鲁祖马布显示胃肠道疾病 (腹),感染和皮肤疾病 (,皮疹) 的信号增加.
- 珀图祖马布加特拉斯图祖马布加多塞塔克塞尔表明胃肠道 (恶心,吐) 和神经系统 (麻醉,神经病变) 的事件增加.
- 观察到带来或延长住院的不良事件的更高率与百图祖马布加特拉斯图祖马布.
结论:
- 确定了与添加祖马布到基于祖马布的治疗相关的不良事件概况.
- 研究结果强调,在开处祖马布组合治疗时,需要考虑这些特定的不良事件.
- 确保HER2阳性乳腺癌治疗中的患者安全至关重要.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
13:59High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
相关概念视频
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Hazard Ratio
For example, in a clinical trial...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
